Tiffany Thorn
CEO, BiVictriX Therapeutics


Established in 2016, BiVictriX Therapeutics Ltd is a North-West based biotech focused on developing and licensing novel, highly-selective, bispecific Antibody Drug Conjugates (ADCs) to target unmet medical need in blood cancer.

ADCs, which were originally coined as the new ‘Magic Bullet’ therapeutics in the field of oncology, are currently limited by their lack of target specificity. BiVictriX has invented a novel targeting strategy, the ‘Dual Targeting Approach’, to improve ADC specificity towards malignant cells through targeting two cell surface antigens simultaneously, expressed solely in a tumour-restricted co-expression pattern.

Matchmaking Information

Processing. Please wait.